Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02346734
Other study ID # HP-00040344
Secondary ID
Status Completed
Phase N/A
First received May 7, 2014
Last updated May 2, 2017
Start date July 2012
Est. completion date April 6, 2017

Study information

Verified date May 2017
Source University of Maryland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study will be to assess the feasibility and patient acceptance of a Home Automated Telemanagement (HAT) system in multiple sclerosis patients.

Our hypothesis is that home telemanagement will be effective and useful in the rehabilitation of multiple sclerosis patients. Specifically, the investigators hypothesize that home telemanagement using a daily exercise diary, monitoring of compliance with a tailored exercise program and regular assessment of strength and motor functions will: 1. Be feasible and acceptable in patients with multiple sclerosis 2. Improve patient compliance with home exercise program 3. Increase patient mobility and motor functions 4. Be a feasible and effective mechanism for affecting multiple sclerosis patient self-efficacy 5. Improve quality of life


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date April 6, 2017
Est. primary completion date April 6, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age: 18-65

- Clinical Diagnosis of MS based on McDonald criteria

- Functional disability defined by the PDDS in the range of 2 to 6

- Have a working telephone line in their home or a cell phone

- Willingness and ability to use MS HAT platform with individual modifications based on preferred user interface

- Patient demonstrates ability to successfully perform physical therapy exercises and procedures independently or with assistance of a caregiver.

- Ability to complete 25-foot walk test in at least 3 minutes

Exclusion Criteria:

- Age less than 18 years old

- No diagnosis of MS

- Other musculoskeletal diagnoses, unstable cardiovascular, respiratory, metabolic or other conditions that would interfere with this study

- One or more exacerbations in the preceding 3 months

- Received a course of steroids (IV or oral) within 60 days of screening

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Multiple Sclerosis Home Automated Telemanagement (MS HAT) system


Locations

Country Name City State
United States University of Maryland Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
University of Maryland Baltimore VA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other The Center for Epidemiologic Studies Depression Scale (CES-D) The Center for Epidemiologic Studies Depression Scale (CES-D) will be used to measure depressive symptoms. CES-D is one of the most common screening tests for depression. This short self-administered test measures depressive feelings and behaviors during the past week. The scale includes 20 items and taps dimensions of depressed mood, feelings of guilt and worthlessness, appetite loss, sleep disturbance, and energy level. These items are assumed to represent the major components of depressive symptoms. 6-month evaluation
Other MOS Patient Adherence Measure MOS Patient Adherence Measure is used to assess a patient's tendency to adhere to a doctor's recommendations during the past 4 weeks. Each item has a 6-point Likert Scale, ranging from 1 (none of the time) to 6 (all of the time). To score general adherence, the responses are averaged after reversing the items 1 and 3. By reversing the scores for items 1 and 3, overall positive aspects of patient adherence are measured. 6-month evaluation
Other Patient-Provider Communication (IPC) Patients perceptions of their patient-provider communication quality will be measured using modified items from the Interpersonal Processes of Care (IPC) questionnaire. The IPC measures multiple facets of patient-provider communication such as general clarity, explanations of conditions and prognoses, and patients' preferences for various treatment options. 6-month evaluation
Other Syme's Social Networks Index (SNI) Social networks will be measured by the widely used Berkman and Syme's Social Networks Index (SNI). The SNI assesses four types of social connections: marital (married or not); sociability (number and frequency of contacts with children, close relatives, and close friends); church group membership (yes versus no); and membership in other community organizations (yes versus no). 6-month evaluation
Primary The Berg Balance Scale (BBS) BBS consists of 14 activities common in daily life and is designed to measure balance in a clinical setting. The patient is asked to perform a task or to sustain a given position for a specific time. Points are deducted if the patient did not fulfill the time or activity requirements or touched an external support or received assistance from the examiner. Each item is rated from 0 to 4, 0 indicating the lowest level of function and 4 indicating the highest level of function. The total score sums up to 56. A score of 45 or above implies that an individual can safely move or walk independently. 6 month evaluation
Secondary Expanded Disability Status Scale (EDSS) Expanded Disability Status Scale (EDSS) was developed for rating overall disability in MS. Patients are graded on the basis of presenting symptoms in eight different functional systems (FS), including pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, mental, and other functions. Scoring of the EDSS uses a 0 to 10, 20-step scale, with 0 equal to normal neurological function, 6.0 requires an assistive device for walking and 10.0 equal to death due to MS. The final score is based on grades obtained in the FS assessment. 6 month evaluation
Secondary 9-Hole Peg Test Measures finger dexterity
Administered by asking the patient to take the pegs from a container, one by one, and place them into the holes on the board, as quickly as possible
Patients must then remove the pegs from the holes, one by one, and replace them back into the container
The board should be placed at the patient's midline, with the container holding the pegs oriented towards the hand being tested
Only the hand being evaluated should perform the test
Hand not being evaluated is permitted to hold the edge of the board in order to provide stability
Scores are based on the time taken to complete the test activity, recorded in seconds
Alternative scoring - the number of pegs placed in 50 or 100 seconds can be recorded. In this case, results are expressed as the number of pegs placed per second
Stopwatch should be started from the moment the participant touches the first peg until the moment the last peg hits the container
6 month evaluation
Secondary Paced Auditory Serial Addition Test The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. It was developed by Gronwell in 1977 and later adapted by Rao and colleagues in 1989 for use in MS. The PASAT is presented using audio cassette tape or compact disk to ensure standardization in the rate of stimulus presentation. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. Shorter inter-stimulus intervals, e.g., 2 seconds or less have also been used with the PASAT but tend to increase the difficulty of the task. Two alternate forms have been developed to minimize possible familiarity with the stimulus items when the PASAT is repeated over more than one occasion. 6-month evaluation
Secondary Patient Determined Disease Steps (PDDS) The PDDS is a patient-reported outcome (PRO) of disability in multiple sclerosis. It has nine ordinal levels ranging between 0 (normal) to 8 (bedridden) and can be classified to mild, moderate and severe disability. 6-month evaluation
Secondary Range of motion Range of motion refers to activity aimed at improving movement of a specific joint. 6-month evaluation
Secondary Lower extremities manual muscle test (LE-MMT) 6-month evaluation
Secondary Functional Mobility 6-month evaluation
Secondary Balance 6-month evaluation
Secondary Gait 6-month evaluation
Secondary Spasticity Scale (Modified Ashworth Scale) Modified Ashworth Scale (MAS). MAS measures the resistance encountered during passive muscle stretching. Its scale ranges from 0 to 4: 0 = No increase in muscle tone; 1 = Slight increase in tone with a catch and release; 1+ = Slight increase in tone, manifested by a catch, followed by minimal resistance; 2 = Marked increase in tone; 3 = Considerable increase in tone; 4 = Rigid in flexion or extension. 6-month evaluation
Secondary Modified Fatigue Impact Scale (MFIS) The Modified Fatigue Impact Scale (MFIS) is used to measure fatigue. The scale consists of 21 items, with 10 items related to mental fatigue, and 11 items relating to physical and social fatigue. The scoring ranges between 0 and 82, a high score reflecting greater impact. In the literature, a cut-off value of 38 has been used to discriminate fatigued from non-fatigued patients. It has shown good validity when compared with the Fatigue Severity Scale, but also appears to be more sensitive to the cognitive and psychosocial aspects of fatigue. 6-month evaluation
Secondary Multiple Sclerosis Walking Scale (MSWS-12) MS Walking Scale (MSWS-12). MSWS-12 is a questionnaire with 12 items, measuring self-reported walking ability in MS. The questions are on limitations to patient's walking due to MS during the past 2 weeks. Each item ranges from 1 to 5 and the higher the sum, the more severe the degree of limitation. 6-month evaluation
Secondary MS Self-efficacy (MSSE) MSSE is a 14-item questionnaire with a 6-point Likert scale, ranging from 1 (strongly disagree) to 6 (strongly agree). Self-efficacy is people's belief about their capabilities to overcome obstacles in life. Total score ranges from 14 to 84, a higher score indicating an elevated level of self-efficacy. 6-month evaluation
Secondary The Timed 25-Foot Walk (T25-FW) The patient is instructed to walk 25 feet as fast and as safely as possible. Then the patient repeats the task by walking back to the starting point. If necessary. assistive devices are allowed to be used. The amount of time (in seconds) that the patient took to walk 25 feet is measured. 6-month Evaluation
Secondary The Six Minute Walk Test (6MWT) The six minute walk test (6MWT) has been widely used as a measure of functional endurance in cadriopulmonary patients and is now being used as a practical and effective outcome measure to examine finctional exercise level in other chronic diseases including MS. Patients are asked to walk along a long, flat, straight, enclosed corridor with turnaround points marked with a cone. 6-month evaluation
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4